



PRESS RELEASE

C2 Therapeutics' Announces 15th Patient Enrollment in its Cryoballoon Focal Ablation System Clinical Trial for Patients with Barrett's Esophagus

Investigators Cite Device Ease of Use and Speed of Procedure as Potential Advantages

Redwood City, Calif. – May 2, 2013 – C2 Therapeutics, a privately held company founded to address the limitations of current Barrett's Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

"C2's Cryoballoon System demonstrates tremendous promise in the elimination of focal BE and restoration of squamous esophageal lining with its combination of usability, safety, and performance," said Professor Bas Weusten, MD, Senior Gastroenterologist, St. Antonius Hospital Nieuwegein and Principal Investigator of the Study. "Early results seem to indicate the resolution of the Barrett's tissue to normal squamous tissue, and I am confident that this trial and future studies will provide favorable assessments to allow broader adoption of this technology by physicians seeking to improve patient outcomes."

The trial is designed to enroll 40 patients in the US and Europe, and the purpose of this international study is to assess the safety, feasibility, and performance of C2's Cryoballoon Ablation System in patients with Barrett's Esophagus. The system is used to ablate focal areas of Barrett's Esophagus at two different doses. Patients will be followed for post-ablation symptoms related to the ablation procedure. At 2 months, patients will receive a follow-up endoscopy where investigators will take biopsy samples of the areas of ablation. Resolution of the Barrett's tissue to normal squamous tissue will be investigated.

C2's technology has been under development for several years and was first used in a human subject in The Netherlands by Jacques Bergman, Professor of GI Endoscopy. It was first used in the United States by Steve DeMeester, Professor of Surgery, at the University of Southern California.

"C2's Cryoballoon Ablation System has been designed to allow for many potential benefits to the patient, the physician, and hospital," said Peter Garcia-Meza, Chief Executive Officer of C2 Therapeutics. "A short and simple procedure due to easy deployment will be advantageous for physicians and patients. Moreover, smaller inventory with no capital equipment will improve capital resource utilization."



Current Barrett's Esophagus (BE) technologies such as Radio Frequency Ablation (RFA) suffer from usability drawbacks such as the need for precise sizing, multiple deployment steps, intensive training for the physician and large controller units. Even with these limitations, the market for these technologies is growing at a rate of 50% annually, and RFA has become the standard of care for certain BE patients.

C2's CryoBalloon Ablation System (System) is designed to address many of the limitations of ablation technologies. The System has three main components – the delivery catheter with balloon probe, a handle, and a small cylinder containing the cryogenic fluid. There is no capital equipment involved – the system is completely single-patient use. The system utilizes one balloon probe for all sizes of esophagi. Access for treatment is simplified as the system utilizes the working channel of the endoscope.

About C2 Therapeutics

C2 Therapeutics was founded in 2007 to address the limitations of current Barrett's Esophagus treatment options. Headquartered in Redwood City, California, C2 is a privately held company whose C2 Cryoballoon Ablation System sets a new standard for simplicity and cost effectiveness in treating Barrett's Esophagus. The device is a TTS (through-the-scope), highly compliant balloon catheter that is simultaneously inflated and cooled by an inert refrigerant delivered from a small disposable handheld unit. The balloon conforms to the shape of the esophageal lumen without exerting excessive tension on the esophageal wall. Operation is intuitive, fast, and cost-effective. The C2 Cryoballoon Ablation System eliminates the need for precise sizing, multiple deployment steps, intensive training for the physician, and large controller units.

For more information on C2 Therapeutics and its products, please visit <http://www.c2therapeutics.com/>.

Contact:

Peter Garcia-Meza, C2 Therapeutics

Ph: 650.521.5304